- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Spring 2020
This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Celgene Corp. v. Mylan Pharms. Inc., 20-0003 (N.D.W.V.) | Jan. 3, 2020 | Hon. Irene M. Keeley | Revlimid® (lenalidomide capsules) | 7,189,740 7,465,800 7,855,217 7,968,569 8,404,717 8,530,498 8,648,095 9,056,120 9,101,621 9,101,622 |
| Exela Pharma Sciences, LLC v. Avadel Legacy Pharms., LLC, 20-0024 (D. Del.) | Jan. 7, 2020 | Hon. Maryellen Noreika | Elcys® (cysteine HCl for injection) Nouress™ (cysteine HCl for injection) | 10,478,453 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 20-0315 (D.N.J.) | Jan. 8, 2020 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 7,968,569 8,530,498 8,648,095 9,101,621 9,101,622 |
| Almirall, LLC v. Zydus Pharms. (USA) Inc., 20-0343 (D.N.J.) | Jan. 9, 2020 | Hon. Freda L. Wolfson | Aczone® (dapsone gel) | 9,517,219 |
| Almirall, LLC v. Mylan Pharms. Inc., 20-0006 (N.D.W.V.) | Jan. 9, 2020 | Hon. Irene M. Keeley | Aczone® (dapsone gel) | 9,517,219 |
| Amgen Inc. v. Torrent Pharma Inc., 20-0065 (D. Del.) | Jan. 16, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 20-0534 (D.N.J.) | Jan. 16, 2020 | Hon. Claire C. Cecchi | Dificid® (fidaxomicin tablets) | 7,906,489 8,586,551 7,378,508 7,863,249 8,859,510 |
| Novartis Pharms. Corp. v. Alembic Pharms. Ltd., 20-0074 (D. Del.) | Jan. 17, 2020 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Amgen Inc. v. Zydus Pharms. (USA) Inc., 20-0075 (D. Del.) | Jan. 17, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 20-20217 (S.D. Fla.) | Jan. 17, 2020 | Hon. Ursula Ungaro | Dificid® (fidaxomicin tablets) | 7,906,489 8,586,551 7,378,508 7,863,249 8,859,510 |
| Vanda Pharms. Inc. v. Apotex Inc., 20-0083 (D. Del.) | Jan. 21, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Amgen Inc. v. Zydus Pharms. (USA) Inc., 20-0678 (D.N.J.) | Jan. 21, 2020 | Hon. Freda L. Wolfson | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., 20-0093 (D. Del.) | Jan. 22, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Amgen Inc. v. Bionpharma, Inc., 20-0105 (D. Del.) | Jan. 23, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Relypsa, Inc. v. Alkem Labs. Ltd., 20-0106 (D. Del.) | Jan. 23, 2020 | Hon. Maryellen Noreika | Veltassa® (patiromer sorbitex calcium powder for oral suspension) | 8,337,824 9,492,476 9,925,212 |
| Merck Sharp & Dohme Corp. v. Sandoz Inc., 20-0783 (D.N.J.) | Jan. 23, 2020 | Hon. Brian R. Martinotti | Noxafil® (posaconazole oral suspension) | 8,263,600 |
| Janssen Products, L.P. v. Zydus Pharms. (USA) Inc., 20-0787 (D.N.J.) | Jan. 23, 2020 | Hon. Freda L. Wolfson | Prezista® (darunavir tablets) | 7,700,645 8,518,987 7,126,015 7,595,408 |
| Amgen Inc. v. Annora Pharma Private Ltd., 20-0122 (D. Del.) | Jan. 24, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Amgen Inc. v. Centaur Pharms. Private Ltd., 20-0123 (D. Del.) | Jan. 24, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Novartis Pharms. Corp. v. Apotex Inc., 20-0133 (D. Del.) | Jan. 28, 2020 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 10,543,179 |
| Sucampo Gmbh v. Zydus Pharms. (USA) Inc., 20-0936 (D.N.J.) | Jan. 28, 2020 | Hon. Freda L. Wolfson | Amitiza® (lubiprostone capsules) | 7,795,312 8,026,393 8,338,639 8,779,187 8,748,481 |
| Amgen Inc. v. MSN Pharms., Inc., 20-0137 (D. Del.) | Jan. 29, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Pfizer Inc. v. Viwit Pharm. Co., Ltd., 20-0160 (D. Del.) | Jan. 31, 2020 | Hon. Colm F. Connolly | Chantix® (varenicline tartrate tablets) | 6,410,550 6,890,927 7,265,119 |
| Silvergate Pharms., Inc. v. CMP Development LLC, 20-0161 (D. Del.) | Jan. 31, 2020 | Hon. Leonard P. Stark | Qbrelis® (Lisinopril oral solution) | 9,463,183 9,616,096 9,814,751 10,039,800 10,265,370 10,406,199 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00368 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 8,163,723 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00369 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 8,168,620 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00370 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 9,259,428 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00371 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 9,901,585 |
| Boehringer Ingelheim Pharms. Inc. v. Mylan Pharms. Inc., 20-0019 (N.D.W.V.) | Feb. 5, 2020 | Hon. Irene M. Keeley | Tradjenta® (linagliptin tablets) | 9,486,526 |
| Boehringer Ingelheim Pharms. Inc. v. Aurobindo Pharma Ltd., 20-0023 (N.D.W.V.) | Feb. 5, 2020 | Hon. John Preston Bailey | Tradjenta® (linagliptin tablets) | 9,486,526 |
| Gilead Sciences, Inc. v. Apotex, Inc., 20-0189 (D. Del.) | Feb. 7, 2020 | Hon. Maryellen Noreika | Vemlidy® (tenofovir alafenamide tablets) Descovy® (emtricitabine / tenofovir alafenamide tablets) Odefsey® (emtricitabine / rilpivirine / tenofovir alafenamide tablets) | 7,390,791 7,803,788 8,754,065 9,296,769 |
| American Regent, Inc. v. Pharmacosmos Therapeutics Inc., 20-1350 (D.N.J.) | Feb. 7, 2020 | Hon. Brian R. Martinotti | Monoferric® (ferric derisomaltose for injection) | 8,431,549 10,478,450 |
| Allergan Sales, LLC v. Breckenridge Pharm., Inc., 20-0199 (D. Del.) | Feb. 10, 2020 | Hon. Mitchell S. Goldberg | Saphris® (asenapine maleate sublingual tablets) | 5,763,476 |
| AstraZeneca AB v. Alembic Pharms. Ltd., 20-0202 (D. Del.) | Feb. 11, 2020 | Hon. Richard G. Andrews | Tagrisso® (osimertinib mesylate tablets) | 10,183,020 |
| Vifor (Int’l) AG v. Mylan Labs. Ltd., 20-1647 (D.N.J.) | Feb. 14, 2020 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) | 10,519,252 |
| Vifor (Int’l) AG v. Sandoz Inc., 20-1649 (D.N.J.) | Feb. 14, 2020 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) | 10,519,252 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 20-0235 (D. Del.) | Feb. 19, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,376,487 |
| Astellas US LLC v. Int’l Medication Systems, Ltd., 20-0273 (D. Del.) | Feb. 25, 2020 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8,106,183 RE47,301 8,524,883 |
| Boehringer Ingelheim Pharms. Inc. v. Annora Pharma Private Ltd., 20-0277 (D. Del.) | Feb. 25, 2020 | Hon. Colm F. Connolly | Glyxambi® (empagliflozin / linagliptin tablets) | 10,258,637 |
| Millennium Pharms., Inc. v. Sun Pharm. Indus. Ltd., 20-0289 (D. Del.) | Feb. 27, 2020 | Hon. Colm F. Connolly | Ninlaro® (ixazomib citrate capsules) | 7,442,830 8,859,504 9,175,017 |
| ViiV Healthcare Co. v. Lupin Ltd., 20-0293 (D. Del.) | Feb. 28, 2020 | Hon. Mitchell S. Goldberg | Juluca® (dolutegravir sodium / rilpivirine HCl tablets) | 9,242,986 10,426,780 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-0300 (D. Del.) | Feb. 28, 2020 | Hon. Leonard P. Stark | Xeljanz® (tofacitinib citrate tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-0301 (D. Del.) | Feb. 28, 2020 | Hon. Leonard P. Stark | Xeljanz XR® (tofacitinib extended-release tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-2222 (D.N.J.) | Feb. 28, 2020 | Hon. Freda L. Wolfson | Xeljanz XR® (tofacitinib extended-release tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-2227 (D.N.J.) | Feb. 28, 2020 | Hon. Freda L. Wolfson | Xeljanz® (tofacitinib citrate tablets) | 6,965,027 7,301,023 RE41,783 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 20-0318 (D. Del.) | Mar. 3, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Takeda Pharms. U.S.A., Inc. v. Alkem Labs. Ltd., 20-0325 (D. Del.) | Mar. 3, 2020 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets)) | 7,906,519 7,935,731 8,093,298 7,964,648 8,093,297 7,619,004 7,601,758 7,820,681 7,915,269 7,964,647 7,981,938 8,093,296 8,097,655 8,415,395 8,415,396 8,440,721 8,440,722 |
| Encore Dermatology Inc. v. Glenmark Pharms. Ltd., 20-2509 (D.N.J.) | Mar. 6, 2020 | Hon. Kevin McNulty | Impoyz® (clobetasol propionate cream) | 9,956,231 |
| Astellas US LLC v. Gland Pharma Ltd., 20-0347 (D. Del.) | Mar. 9, 2020 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8,106,183 RE47,301 8,524,883 |
| Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., 20-2576 (D.N.J.) | Mar. 10, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Celgene Corp. v. Apotex Inc., 20-2593 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Breckenridge Pharm., Inc., 20-2597 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Hetero Labs Ltd., 20-2601 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 20-2606 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 20-2607 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Mylan Pharms. Inc., 20-2608 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Teva Pharms. USA, Inc., 20-2614 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Bausch Health US, LLC v. Aleor Dermaceuticals Ltd., 20-2735 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Alkem Labs. Ltd., 20-2737 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Aurobindo Pharma USA Inc., 20-2738 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Amneal Pharms. LLC v. Cubist Pharms. LLC, IPR2020-00193 (PTAB) | Nov. 27, 2019 | N/A | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Bausch Health US, LLC v. KVK-Tech, Inc., 20-2742 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Lupin Ltd., 20-2744 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Strides Pharma Inc., 20-2746 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Taro Pharms. U.S.A., Inc., 20-2747 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Zydus Pharms. (USA) Inc., 20-2748 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Mylan Pharms. Inc., 20-2749 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Merck Sharp & Dohme B.V. v. Gland Pharma Ltd., 20-2750 (D.N.J.) | Mar. 12, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Teva Pharms. USA, Inc., 20-2751 (D.N.J.) | Mar. 12, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Braintree Labs., Inc. v. Alkem Labs. Ltd., 20-0362 (D. Del.) | Mar. 13, 2020 | Hon. Colm F. Connolly | Suprep® Bowel Prep Kit (sodium sulfate / potassium sulfate / magnesium sulfate oral lavage solution) | 6,946,149 |
| Merck Sharp & Dohme B.V. v. Lupin Ltd., 20-2786 (D.N.J.) | Mar. 13, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Mankind Pharma Ltd., 20-2787 (D.N.J.) | Mar. 13, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 6,949,527 |
| Bausch Health US, LLC v. Mylan Pharms. Inc., 20-0046 (N.D.W.V.) | Mar. 13, 2020 | Hon. Irene M. Keeley | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Exela Pharma Sciences, LLC v. Eton Pharms., Inc., 20-0365 (D. Del.) | Mar. 16, 2020 | Hon. Maryellen Noreika | Elcys® (cysteine HCl for injection) | 10,478,453 10,583,155 |
| Merck Sharp & Dohme B.V. v. Fresenius Kabi USA, LLC, 20-2892 (D.N.J.) | Mar. 16, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Braintree Labs., Inc. v. Alkem Labs. Ltd., 20-2904 (D.N.J.) | Mar. 16, 2020 | Hon. Peter G. Sheridan | Suprep® Bowel Prep Kit (sodium sulfate / potassium sulfate / magnesium sulfate oral lavage solution) | 6,946,149 |
| Merck Sharp & Dohme B.V. v. Dr. Reddy’s Labs., Inc., 20-2909 (D.N.J.) | Mar. 16, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Fisiopharma S.R.L., 20-2964 (D.N.J.) | Mar. 17, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Sun Pharm. Indus., Inc., 20-3007 (D.N.J.) | Mar. 18, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Hoffmann-La Roche, Inc. v. Fresenius Kabi USA, LLC, 20-0394 (D. Del.) | 19-Mar-20 | Hon. Richard G. Andrews | Alcensa® (alectinib HCl capsules) | 9,126,931 9,440,922 9,365,514 10,350,214 |
| Merck Sharp & Dohme B.V. v. Zydus Pharms. (USA) Inc., 20-3068 (D.N.J.) | Mar. 19, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. USV Private Ltd., 20-3072 (D.N.J.) | Mar. 19, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Pharmacyclics LLC v. Sun Pharma Global FZE, 20-0403 (D. Del.) | Mar. 20, 2020 | Hon. Colm F. Connolly | Imbruvica® (ibrutinib tablets) | 10,478,439 |
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA, Inc. 20-3102 (D.N.J.) | Mar. 20, 2020 | Hon. Renee Marie Bumb | Invokamet XR® (canagliflozin / metformain HCl extended-release tablets) | 7,943,582 8,513,202 |
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA, Inc. 20-3106 (D.N.J.) | Mar. 20, 2020 | Hon. Freda L. Wolfson | Invokamet XR® (canagliflozin / metformain HCl extended-release tablets) | 7,943,788 8,222,219 8,785,403 |
| Merck Sharp & Dohme B.V. v. Aspiro Pharma Ltd., 20-3112 (D.N.J.) | Mar. 20, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 6,949,527 |
| Merck Sharp & Dohme B.V. v. Sandoz Inc., 20-3117 (D.N.J.) | Mar. 20, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Cubist Pharms. LLC v. Mylan Pharms Inc., 20-3168 (D.N.J.) | Mar. 23, 2020 | Hon. Brian R. Martinotti | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Novartis Pharms. Corp. v. Lupin Atlantis Holdings, S.A., 20-0415 (D. Del.) | Mar. 24, 2020 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Cubist Pharms. LLC v. Mylan Pharms. Inc., 20-0052 (N.D.W.V.) | Mar. 24, 2020 | Hon. Irene M. Keeley | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 20-3229 (D.N.J.) | Mar. 25, 2020 | Hon. Michael A. Shipp | Sprycel® (dasatinib tablets) | 7,491,725 |
| Merck Sharp & Dohme B.V. v. Mylan API US LLC, 20-3270 (D.N.J.) | Mar. 25, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Salix Pharms., Ltd. v. Norwich Pharms., Inc., 20-0430 (D. Del.) | Mar. 26, 2020 | Hon. Richard G. Andrews | Xifaxan® (rifaximin tablets) | 7,045,620 7,612,199 7,902,206 7,906,542 7,915,275 8,158,644 8,158,781 8,193,196 8,309,569 8,518,949 8,642,573 8,741,904 8,829,017 8,835,452 8,853,231 8,946,252 8,969,398 9,271,968 9,421,195 9,629,828 10,314,828 10,335,397 10,456,384 |
| Ferring Pharms. Inc. v. Fresenius Kabi USA, LLC, 20-0431 (D. Del.) | Mar. 26, 2020 | Hon. Maryellen Noreika | Firmagon® (degarelix for injection) | 9,579,359 9,415,085 8,841,081 9,877,999 8,828,938 |
| Merck Sharp & Dohme B.V. v. MSN Labs. Private Ltd., 20-3314 (D.N.J.) | Mar. 26, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Mallinckrodt Hospital Products IP Ltd. v. Baxter Healthcare Corp., 20-0434 (D. Del.) | Mar. 27, 2020 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 9,399,012 9,610,265 9,987,238 10,383,834 6,992,218 |
GENERICally Speaking Spring 2020
Related Professionals
GENERICally Speaking Spring 2020
VOL. 9, NO. 4 Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.